BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37248957)

  • 21. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm.
    Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W
    Front Immunol; 2022; 13():843408. PubMed ID: 35693827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
    Gao B; Wang Y; Li C; Lu S
    Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.
    Li C; Cui X; Li Y; Guo D; He S
    Sci Rep; 2023 May; 13(1):8681. PubMed ID: 37248280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Heterogeneity of Immune Cell Infiltration Landscape and Its Immunotherapeutic Implications in Hepatocellular Carcinoma.
    Guo Y; Yang J; Ren K; Tian X; Gao H; Tian X; Zhang X; Kan Q
    Front Immunol; 2022; 13():861525. PubMed ID: 35355983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes.
    Wan S; Lei Y; Li M; Wu B
    Hepatol Int; 2022 Feb; 16(1):112-124. PubMed ID: 34449009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ferroptosis-Related Genes with Regard to CTLA-4 and Immune Infiltration in Hepatocellular Carcinoma.
    Xu J; Wu X; Wang X
    Biochem Genet; 2023 Apr; 61(2):687-703. PubMed ID: 36094606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.
    Liu L; Jin H; Dong M; Tian J; Li H; Liu Q; Chen Y; Zou Z
    Apoptosis; 2022 Dec; 27(11-12):946-960. PubMed ID: 36028785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
    Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
    Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
    Yu X; Chen P; Yi W; Ruan W; Xiong X
    Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a Ferroptosis-Related Long Noncoding RNA Prognostic Signature and Its Predictive Ability to Immunotherapy in Hepatocellular Carcinoma.
    Wang L; Ge X; Zhang Z; Ye Y; Zhou Z; Li M; Yan H; Wu L; Bai Q; Li J; Zhu J; Wang Y
    Front Genet; 2021; 12():682082. PubMed ID: 34745200
    [No Abstract]   [Full Text] [Related]  

  • 33. A prognostic risk model, tumor immune environment modulation, and drug prediction of ferroptosis and amino acid metabolism-related genes in hepatocellular carcinoma.
    Ji L; Zhang Q; Cao Y; Liu L
    Hum Cell; 2023 May; 36(3):1173-1189. PubMed ID: 36892792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization and clinical verification of immune-related genes in hepatocellular carcinoma to aid prognosis evaluation and immunotherapy.
    Qu J; Sun F; Hou Y; Qi H; Sun X; Xing L
    BMC Cancer; 2023 Jun; 23(1):549. PubMed ID: 37322434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
    Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
    Front Immunol; 2022; 13():862527. PubMed ID: 35493471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and Validation of Ferroptosis-Related Subtypes and a Predictive Signature in Hepatocellular Carcinoma.
    Zheng C; Peng Y; Wang H; Wang Y; Liu L; Zhao Q
    Pharmgenomics Pers Med; 2023; 16():39-58. PubMed ID: 36726530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
    Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
    BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
    Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
    Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden.
    Tang B; Zhu J; Zhao Z; Lu C; Liu S; Fang S; Zheng L; Zhang N; Chen M; Xu M; Yu R; Ji J
    J Adv Res; 2021 Nov; 33():153-165. PubMed ID: 34603786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.